ASH 2020 Phase 1 Study of MGD013 (Tebotelimab, PD 1 x LAG 3) in Patients with RR DLBCL (Wang)

MacroGenics Inc. published this content on December 06, 2020, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 23, 2025 at 16:41 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]